Ceftobiprole-A novel cephalosporin to combat MRSA

Abstract

Abstract. Gram positive cocci are responsible for a large number of infections, involving the skin and skin structures, respiratory tract, bloodstream etc., both in the community as well as in the hospital settings. However, the recent emergence of multidrug resistant strains has compromised therapeutic options as well as made therapy less effective and costlier. As medicine continues to evolve to combat these pathogens, they always seem to be a step ahead of us. Vancomycin, the drug of choice for resistant strains of gram positive cocci, has also seen the development of bacteria resistant to it. The introduction of ceftobiprole, a novel fifth-generation cephalosporin, has brought with it new hope for combating these pathogens. It exerts its antibacterial effect by binding to the PBP (penicillin-binding protein), blocking formation of the bacterial cell wall and ultimately leading to cell lysis and death. It has also got a wide antibacterial spectrum covering many gram negative bacteria as well as anaerobes. Ceftobiprole has been evaluated in various clinical trials including the multicentric STRAUSS 1 and 2 trials, and the results have demonstrated favourable efficacy of ceftobiprole against gram positive cocci. Thus, although ceftobiprole provides us with another option in our battle against the microbes, its judicious use is imperative so that we do not run out of therapeutic options in the near future.

Key words: ceftobiprole, MRSA, cephalosporin, cocci.

Keywords

• ceftobiprole, MRSA, cephalosporin, cocci

Kaynakça

1. Kontou P, Kuti JL, Nicolau DP. Ceftobiprole. The first anti-MRSA cephalosporin antibiotic. Formulary 2008; 32: 66-78.
2. Kisgen J, Whitney D. Ceftobiprole, a Broad- Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA). PT 2008; 33: 631-641.
3. Mehta AA, Rodrigues CC, Kumar RR, et al. A pilot programme of MRSA surveillance in India. (MRSA Surveillance Study Group). J Postgrad Med 1996; 42: 1-3.
4. Tyagi A, Kapil A, Singh P. Incidence of methicillin resistant Staphylococcus aureus (MRSA) in pus samples in a tertiary care hospital, AIIMS, New Delhi. J Indian Acad Clin Med 2008; 9: 33-35.
5. Vidhani S, Mehndiratta PL, Mathur MD. Study of methicillin resistant Staphylococcus aureus (MRSA) isolates from high risk patients. Indian J Med Microbiol 2001; 19: 87-90.
6. Verma S, Joshi S, Chitnis V, Hemwani N, Chitnis D. Growing problem of methicillin resistant staphylococci - Indian scenario. Indian J Med Sci 2000; 54: 535-540.
7. Choudhary U, Anupama. Prevalence of methicillin resistance in Staphylococcus aureus. Indian J Med Microbiol 1999; 17: 154-155.
8. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666-674.

9. Hsueh PR, Teng LJ, Chen WH, et al. Increasing prevalence of methicillin-resistant Staphylococcus aureus causing nosocomial infections at a university hospital in Taiwan from 1986 to 2001. Antimicrob Agents Chemother 2004; 48: 1361- 1364.
10. Elsaghier AA, Aucken HM, Hamilton-Miller JM, Shaw S, Kibbler CC. Resistance to teicoplanin developing during treatment of methicillin- resistant Staphylococcus aureus infection. J Antimicrob Chemother 2002; 49: 423-424.
11. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin- resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
12. Utsui Y, Yokota T. Role of an altered penicillin- binding protein in methicillin- and cephem- resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985; 28: 397-403.
13. Adis R&D profile Ceftobiprole medocaril. Drugs RD 2006; 7: 305-311. Available at adisonline.com
14. Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis 2006; 6: 156.
15. Saha B, Singh AK, Ghosh A, Bal M. Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol 2008; 57: 72-79.
16. Nathwani D, Tillotson GS. Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era? Int J Antimicrob Agents 2003; 21: 521-524.
17. James ME. In vitro profile of a new β-lactam, ceftibiprole, with activity against methicillin- resistant Staphylococcus aureus. Clin Microbiol Infect 2007; 13: 17-24.
18. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002; 50: 915-932.
19. Bustos C, Pozo JLD. Emerging agents to combat complicated and resistant infections: focus on ceftobiprole. Infection Drug Resist 2010; 3: 5-14.
20. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49: 4210-4219.
21. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003; 52: 864-868.
22. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 884-888.
23. Murthy B, Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti- MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 2008; 47: 21-33.
24. Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 2570-2575.
25. Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 2576-2580.
26. Schmitt-Hoffman AH, Roos B, Heep M, et al. Influence of gender on the pharmacokinetics of BAL9141 after intravenous infusion of pro-drug BAL5788. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases; May 1-4, 2004; Prague, Czech Republic. Abstract P1030.
27. Roos B, Schmidt-Hoffman A, Schleimer M. Safety and pharmacokinetics of BAL5788 in healthy subjects with normal or impaired renal function. Presented at the 43rd Annual Inter-science Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Abstract A-23.
28. Lodise TP Jr, Pypstra R, Kahn JB, et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 2007; 51: 2378-2387.
29. Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect 2007; 13: 25-29.
30. Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008; 52: 37-44.
31. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46: 647-655.
32. Nicholson SC, Strauss RS, Michiels B, Noel GJ. Efficacy of ceftobiprole for the treatment of severely ill patients hospitalized with community- acquired pneumonia. Presented at the American Thoracic Society International Conference; May 16-21, 2008; Toronto. Poster C-17.
33. Basilea announces positive top-line data from phase III study of ceftobiprole in hospital-acquired pneumonia. Basel: Basilea Pharmaceutica Ltd.; October 9, 2007. Available at www.basilea.com
34. Arias CA, Singh KV, Panesso D, Murray BE. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta- lactamase-producing and vancomycin-resistant isolates. Antimicrob Agents Chemother 2007; 51: 2043-2047.
35. Issa NC, Rouse MS, Piper KE, et al. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Diagn Microbiol Infect Dis 2004; 48: 73-75.
36. Pillar CM, Aranza MK, Shah D, Sahm DF.In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother 2008; 61: 595-602.
37. Bogdanovich T, Clark C, Ednie L, et al. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 2006; 50: 2050-2057.
38. Hebeisen P, Heinze-Krauss I, Angehrn P, et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001; 45: 825-836.
39. Ednie L, Shapiro S, Appelbaum PC. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin. Diagn Microbiol Infect Dis 2007; 58: 133-136.
40. Borg MA, de Kraker M, Scicluna E, et al. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in invasive isolates from southern and eastern Mediterranean countries. J Antimicrob Chemother 2007; 60: 1310-1315.
41. Fadeyi A, Bolaji BO, Oyedepo OO, et al. Methicillin-resistant Staphylococcus aureus carriage among health care workers of the critical care units in a Nigerian hospital. Am J Infect Dis 2010; 6: 18-23.
42. Kresken M, Brauers J, Korber-Irrgang B, Menke A, Romfeld C. In vitro activity of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa by time-kill methodology. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2007; Chicago, IL, USA. Poster E- 273. www. Antiinfectives – intelligence .de / de / wirueberuns 6.2.html
43. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2974-2976.
44. Rodvold KA, Nicolau DP, Lodise TP, et al. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob Agents Chemother 2009; 53: 3294- 3301.
45. Cottagnoud M, Acosta F, Stuki F, Gerber P, Cottagnoud PH. Ceftobiprole is superior to cefepime against a Klebsiella pneumoniae strain in experimental meningitis. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases; April 2008; Barcelona, Spain. Abstract P1933. www. blackwellpublishing. com/eccmid18/abstract.asp?id=69831.
46. Hawkey PM. The origins and molecular basis of antibiotic resistance. BMJ 1998; 317: 657-660.